MEDICAL DEVICE MANUFACTURER D I S P O S A B L E M E D I C A L T R A Y • Excellent wear resistance that can sustain a minimum of 2,000 rotations • Withstand freezing temperature as low as -20°C • Can be sterilized by EtO • Delivered excellent wear resistance performance to fully meet customer’s request • Provided dimensional stability required for this medical application • Reduced friction to lower the noise during operation LubriOne™ Internally Lubricated Formulation KEY REQUIREMENTS WHY AVIENT?

View PDF The SQS herewith attests that the organisation named below has a management system that meets the requirements of the normative base mentioned. 70 01 _1 /A pr il 20 22 /V er si on 2 .0 Certificate Avient Colorants Spain S.A.

AVIENT SOLUTION LIGHTWEIGHTING + CYCLE TIME LEARN MORE • Achieved average weight reduction across molds of 7.75% • Achieved cycle time reduction of 15-20% • Provided key support with equipment and processing • Reduced energy consumption • Projected savings of $500,000 annually KEY REQUIREMENTS • Lightweighting • Cycle time improvement • Processing support to enable a seamless transition to begin using foam Copyright © 2020, Avient Corporation.

_2 /Ju n- 20 19 /V er si on 1 .0 Certificate Avient Colorants Singapore Pte Ltd 8 Third Chin Bee Road Jurong Industrial Estate 618684 Singapore Singapore Scope Administration, Site management, Manufacture, Laboratory, Procurement, Maintenance, infrastructure, Warehouse and Transport Normative base EN ISO 13485:2016 Medical devices – Quality Management System Reg. no. 45483 Validity 01. 03. 2022 – 28. 02. 2025 Issue 01. 03. 2022 A.Grisard, President SQS F.

Müller, CEO SQS 66 60 _2 / J un e 20 19 / V er si on 2 .0 Swiss Association for Quality and Management Systems (SQS) Bernstrasse 103, 3052 Zollikofen, Switzerland A.

View PDF The SQS herewith attests that the organisation named below has a management system that meets the requirements of the normative base mentioned. 70 01 _1 /A pr il 20 22 /V er si on 2 .0 Certificate P.T.

Richardson Executive Vice President, Chief Financial Officer PolyOne Corporation Page 15 Track Record of Accelerated Growth Total Revenue Adjusted EPS Adjusted EBITDA $2,061 $2,506 $2,709 $2,861 $3,771 2009 2010 2011 2012 2013 ($ in millions, except EPS ) $105 $179 $202 $255 $344 2009 2010 2011 2012 2013 $0.13 $0.68 $0.82 $1.00 $1.31 2009 2010 2011 2012 2013 PolyOne Corporation Page 16 $0.31 $0.44 $0.20 $0.30 $0.40 Q1 2013 Q1 2014 Adjusted EPS $42 $60 $20 $40 $60 Q1 2013 Q1 2014 Specialty Operating Income ($ millions) Q1 2014 Financial Highlights  Growth momentum accelerates driven by specialty platform  Specialty segments and Distribution achieve record results  All segments increase operating income compared to prior year  Revenue grew 25% versus Q1 2013 +43% +42% $57 $79 $30 $60 $90 Q1 2013 Q1 2014 Adjusted Operating Income ($ millions) +39% PolyOne Corporation Page 17 Commitment to Operational Excellence 81% 96% 2006 2013 16.2% 10.9% 2006 2013 On-Time Delivery Working Capital % of Sales 5.0% 31.0% 2006 2013 Percent of Associates Trained in LSS  Three consecutive years – CFO Magazine Best Working Capital Management Program in the chemical industry World’s Best Business Process Excellence Program in 2012*  95 certified Black Belts  211 certified Green Belts  422 Project Leaders World’s Best “Start-up Program” for Lean Six Sigma Deployment in 2009* *Both awards received from International Quality and Productivity Center PolyOne Corporation Page 18 Debt Maturities & Pension Funding – 3/31/14 Net Debt / EBITDA* = 1.9x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of March 31, 2014 ($ millions) Coupon Rates: 7.500% 7.375% 5.250% *TTM 12/31/2013 ** includes US-qualified pension plans only 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2014 Pension Funding** As of March 31, 2014 PolyOne Corporation Page 19 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return $0.16 $0.20 $0.24 $0.32 $0.10 $0.20 $0.30 $0.40 2011 2012 2013 2014 Annual Dividend Expanding our sales, marketing, and technical capabilities Targets that expand our: • Specialty offerings • End market presence • Geographic footprint • Operating Margin Synergy opportunities Adjacent material solutions Repurchased 1.4 million shares in Q1 2014 Repurchased 6.4 million shares since April 2013  13.6 million shares are available for repurchase under the current authorization Organic Growth Acquisitions Share Repurchases Dividends  Investing in operational and LSS initiatives (including synergy capture) Manufacturing alignment PolyOne Corporation Page 20 3.07 3.05 1.81 1.45 1.82 1.54 0.85 3.15 1.17 1.69 0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 0.91 PolyOne Valuation Aspirations PEG Ratio Comparison Represents $38 of share price upside Avg = 1.96 PolyOne Corporation Page 21 Innovating for the Future Dr. Christopher Murphy Vice President, Research and Development Chief Innovation Officer PolyOne Corporation Page 22 2 lbs Plastic = 3 lbs aluminum or 8 lbs steel or 27 lbs glass 33% less material by weight than aluminum 75% less material by weight than steel 93% less material by weight than glass Requires 91% less energy to recycle a pound of plastic versus a pound of paper Source: SPI: Sustainability and the Plastics Industry Plastics: Key to Future Sustainable Development PolyOne Corporation Page 23 Decreasing Dependence on Fossil Fuels Globalizing and Localizing • Aging population • Longer life expectancy • Healthy living • Aging in place • Environmental consciousness • Alternative energy • Resource efficiency • Biotechnology • Global leader/local expert with customized solutions • Global OEMs seeking one standard of service everywhere • Efficiency focus • Reduced size/weight • Mass transit • Alternative materials • Electric vehicles Protecting the Environment Improving Health and Wellness Alignment with Megatrends PolyOne Corporation Page 24 Innovation Drives Earnings Growth $20 $53 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* *Percentage of Specialty Platform revenue from products introduced in last five years 14.3% 30.7% 2006 2013 Specialty Platform Gross Margin % 19.5% 43.0% 2006 2013 PolyOne Corporation Page 25 Prototype Frame Opportunity Scale-up & Test Market Build Business Case Commercial Launch Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 4 11 5 10 6 9 3 4 2 15 9 1 10 4 Breakthrough Platform Derivative A Rich Pipeline of Opportunity Number of Projects 25 14 19 17 18 93 Addressable Market ($ millions) TBD TBD $800 $450 $450 $1,700 PolyOne Corporation Page 26 Recent Innovations Aligned with Megatrends in Key End Markets and 2015 Goals Robert M. Patterson President and Chief Executive Officer PolyOne Corporation Page 36 PolyOne Core Values Innovation Collaboration Excellence PolyOne Corporation Page 37 Innovation Drives Earnings Growth $20 $53 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* *Percentage of Specialty Platform revenue from products introduced in last five years 14.3% 30.7% 2006 2013 Specialty Platform Gross Margin % 19.5% 43.0% 2006 2013 PolyOne Corporation Page 38 Formula for Success Innovation Market Beating Performance Excellence in Execution PolyOne Corporation Page 39 Track Record of Successful Integrations and Rapid Operating Income Growth $12 $44 2007 2013 $22 $30 2012 2013 $24 $49 2012 2013 GLS ColorMatrix Spartech OI in $ millions PolyOne Corporation Page 40 2015 and Beyond Innovation will drive the next stage in our remarkable transformation Deliver on 2015 goals Expand Specialty offerings and possibilities Identified as a truly global, specialty chemical company Market Potential Exceeds $40 Billion PolyOne Corporation Page 41 Driving Toward Premier Profitability EBIT Margins for top tier companies Victrex 42% Sigma Aldrich 18% FMC 25% IFF 18% Eastman 17% Hexcel 16% 16% Rockwood Holdings Celanese 14% 7% EBIT Margin – 2013 Albemarle 24% Ecolab 13% PolyOne Corporation Page 42 Bright Future & High Aspirations – The Next Seven Years • % OP Income from Specialty - 5% • Market Cap - $500 Million • Revenue - $2.6 Billion • Commodity Peers • Specialty ROS - 1.5% • % OP Income from Specialty - 62% • Market Cap - $3.5 Billion • Revenue - $3.7 Billion • Specialty ROS - 9.4% • % OP Income from Specialty - 80 to 90% • Market Cap - $12 to $18 Billion • Revenue - $8 to $10 Billion • Specialty Peers • Specialty ROS - ≥ 20% 2000 – 2006 2007 – 2013 2014 – 2020 PolyOne Corporation Page 43 The New PolyOne: A Specialty Growth Company Why Invest In PolyOne?

Just a few months ago, we completed the acquisition of the Clariant Masterbatch business, the largest acquisition in the 20-year history of our company. INVESTMENT IN COMMERCIAL RESOURCES D R I V E S I N N O VAT I V E P R O D U C T P O R T F O L I O AN D S AL E S G R O W T H 2.6x TARGET NET LEVERAGE BY 2021 ~$1Bn REPURCHASED OVER LAST 10 YEARS ~$350MM PAID OVER LAST 10 YEARS RETURNING VALUE TO SHAREHOLDERS 12 Free Cash Flow Dividends Share Repurchases Deleveraging Strong track record of cash generation put to work in M&A and return to shareholders while modestly levered 0.16 0.20 0.26 0.34 0.42 0.50 0.58 0.72 0.79 0.81 11 12 13 14 15 16 17 18 19 20 0.1 0.1 0.2 0.5 0.6 0.7 0.8 0.9 0.9 1.0 11 12 13 14 15 16 17 18 19 20 3.1x 2.6x 2020PF* 2021E Growing Dividend Cumulative Buybacks Net Leverage $B n $ p e r sh ar e *2020 estimate and Pro forma for acquisition of the Clariant Masterbatch business Cash Generation 19 160 240 2011 2019 2020E ~$240MM Another unique value creation lever at Avient is synergy capture with our recent acquisition of Clariant Masterbatch. Synergies Initial Estimate ($ Millions) Revised Estimate ($ Millions) Administrative $ 18 $ 20 Sourcing 24 30 Operational 18 25 Total Synergies $ 60 $ 75 CLARIANT INTEGRATION & COST SYNERGIES UPDATE 13 $1.65 $2.00 2020E Organic 2020 PF 2020 PF w/ Synergies The cost synergies from the Clariant Masterbatch acquisition will help drive substantial margin expansion.

Purchase price multiple rapidly declining on strength of business and synergy capture (1) (1) (1) (1) (1) (1) (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition ($ in millions) 7 SEM CAI Avient • Composites and Outdoor High Performance applications drove positive mix within SEM • Clariant Masterbatch synergy realization under way and expected to drive further margin expansion in 2021 • Portfolio transformation to high growth end markets with focus on sustainable solutions megatrend 10.1% 11.8% 2019PF 2020 (1) (1) EBITDA MARGIN EXPANSION Distribution 6.3% 6.0% 15.2% 17.6% 11.1% 12.1% 2019PF 2020PF 14.5% 19.8% 13.5% 16.1% 6.4% 6.3% 15.2% 16.2% (1) (1) Full YearQ4 (2) (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition (2) Total company reflects adjusted EBITDA margins SPOTLIGHT: COMPOSITES 8 • SEM delivers a record year in 2020 – 13% operating income growth and over 200 bps in margin expansion year-over-year • Prior investments in composites platform and outdoor high performance applications paying off, resulting in substantial growth over the last two years SEM Operating Income (OI % of Sales) ($ in millions) $(0.1) $(1.0) $2.2 $19.1 $26.8 2016 2017 2018 2019 2020 Composites Performance (Operating Income) $83.7 $94.4 2019 2020 (11.2%) (13.3%) 0.1 0.1 0.2 0.5 0.6 0.7 0.8 0.9 0.9 1.0 11 12 13 14 15 16 17 18 19 20 $19 $160 $338 2011 2019 2020 0.16 0.20 0.26 0.34 0.42 0.50 0.58 0.72 0.79 0.81 0.85 11 12 13 14 15 16 17 18 19 20 21E FREE CASH FLOW AND CAPITAL ALLOCATION 9 Free Cash Flow Dividends Share Repurchases Deleveraging 3.5x 2.7x 2019PF 2020PF Growing Dividend Cumulative Buybacks Net Leverage $B n $ p e r sh ar e Cash Generation (1) (1) ~$1Bn REPURCHASED OVER LAST 10 YEARS ~$350MM PAID OVER LAST 10 YEARS ~$338MM 2.7x NET LEVERAGE (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition GREAT PLACE TO WORK! 10 2021 O U TLO O K Synergies ($ millions) Initial Three-Year Estimate Revised Three-Year Estimate 2021 Expected Realization Administrative $ 18 $ 20 $ 15 Sourcing 24 30 15 Operational 18 25 5 Total Synergies $ 60 $ 75 $ 35 CLARIANT INTEGRATION & COST SYNERGIES UPDATE 12 • Integration going extremely well: synergy target increased from $60 million to $75 million • $5 million of synergies in 2020 and expect to realize $35 million in 2021 • Relentless focus on guiding principles of safety first, employee collaboration and exceeding customer expectations • Future revenue synergies are not part of these estimates and represent additional growth over the long term $86 $103 2020PF 2021E $0.53 $0.70 2020PF 2021E ORGANIC GROWTH PROJECTIONS – Q1 (TOTAL COMPANY) 13 Sales Adjusted Operating Income $991 $1,090 2020PF 2021E + 10% Adjusted EPS + 20% + 32% (in millions) (in millions) (1) (1) (1) (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition $308 $360 2020PF 2021E $1.93 $2.40 2020PF 2021E ORGANIC GROWTH PROJECTIONS – FULL YEAR (TOTAL COMPANY) 14 Sales Adjusted Operating Income $3,783 $4,100 2020PF 2021E + 8% Adjusted EPS + 17% + 24% (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition (1) (1) (in millions) (in millions) (1) 2020 Pro forma $3,783 $308 Sustainable Solutions 60 11% 24 Healthcare 60 11% 18 Composites 20 10% 10 Growth in Emerging Regions 50 7% 11 Other (GDP growth) 82 5% 11 Sub-total $4,055 7% $382 COVID Response Applications (25) - (11) Outdoor High Performance Applications (15) - (7) Asia Payroll Tax Subsidy (COVID) - - (4) FX Impact 85 - 7 Synergies - - 30 Incentives, Travel, Other Employee Costs - - (37) 2021 Estimated $4,100 8% $360 2021 ORGANIC SALES AND OPERATING INCOME (TOTAL COMPANY) 15 (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition (2) COVID Response Applications: facemasks, personal protective equipment Sales Growth Rate Adjusted Operating Income$ millions (1) (2) CASH FLOW AND LEVERAGE 16 • Asset light business generates significant free cash flow • Cash generation in 2021 partially offset by restructuring activities to capture synergies associated with the Clariant Masterbatch acquisition • Cash flow deployed to M&A, opportunistic share repurchases and balance sheet / leverage reduction 3.5x 2.7x 2.1x 2019PF 2020PF 2021E Net Debt / Adjusted EBITDA (1) (1) (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition ($ millions) 2020 2021E Adjusted EBITDA 382 510 Working Capital: Source / (Use) 116 (30) Cash Taxes (40) (53) Interest Paid (67) (76) CapEx (62) (75) CapEx for Synergy Capture (2) (20) Restructuring for Synergy Capture (11) (25) Other 22 19 Free Cash Flow 338 250 We sell solutions not commodities. That’s Avient. 21,000+ CUSTOMERS >75% ARE CUSTOMIZED SOLUTIONS TO UNIQUE SPECIFICATIONS of sales 18 AVIENT’S VALUE CREATION LEVERS 19 Exposure to high growth end markets Investment in commercial resources and innovation Strong free cash flow generation / capital deployment Clariant Masterbatch synergies COVID recovery Re-Rating: Current share price valuation Avient is poised for near-term and long-term shareholder value creation. 20 • 8% increase in sales drives 24% increase in adjusted EPS to $2.40 ($2.70 excluding step-up depreciation and amortization) as a result of continued growth in sustainable solutions and synergy capture • Clariant synergy capture ahead of schedule: $35M of savings planned from Clariant Masterbatch acquisition • Adjusted EBITDA of $510M – highest level in company history • Deleveraging ahead of schedule – 2.1x net debt to adjusted EBITDA by the end of 2021 2021 PROJECTIONS PEER COMPARISONS 21 As a specialty formulator, we don’t require significant capital investment, as compared to the base resin raw material suppliers we purchase from.

subject= mailto:Ethics.Officer%40avient.com%20? subject= mailto:%20Legal.Officer%40avient.com%20%20? subject= mailto:%20Legal.Officer%40avient.com%20%20?